Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) is one of 70 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Guided Therapeutics to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, earnings, profitability and analyst recommendations.
Volatility & Risk
Guided Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ competitors have a beta of 18.19, suggesting that their average share price is 1,719% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Guided Therapeutics and its competitors, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Guided Therapeutics | 0 | 0 | 0 | 0 | N/A |
Guided Therapeutics Competitors | 266 | 797 | 1962 | 58 | 2.59 |
Institutional and Insider Ownership
9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 45.8% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by company insiders. Comparatively, 13.5% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Guided Therapeutics and its competitors top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Guided Therapeutics | $100,000.00 | -$3.49 million | -5.83 |
Guided Therapeutics Competitors | $1.08 billion | $91.03 million | 91.93 |
Guided Therapeutics’ competitors have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Guided Therapeutics and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Guided Therapeutics | N/A | N/A | -138.23% |
Guided Therapeutics Competitors | -344.53% | -46.15% | -24.71% |
Summary
Guided Therapeutics competitors beat Guided Therapeutics on 7 of the 10 factors compared.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.